COMMUNIQUÉS West-GlobeNewswire

-
XBiotech Announces First Patient in Clinical Study to Evaluate Bermekimab in Systemic Sclerosis
02/10/2019 - 14:59 -
Eyenovia to Participate in Multiple Upcoming Medical Meetings
02/10/2019 - 14:30 -
Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit
02/10/2019 - 14:30 -
CellaVision completes the acquisition of RAL Diagnostics
02/10/2019 - 14:30 -
Predictive Oncology Inc. Announces Pricing of Public Offering of Up to $3,167,768.50 of Common Stock
02/10/2019 - 14:27 -
Dabir Surfaces Inc. Announces Master Product Agreement with Trinity Health
02/10/2019 - 14:26 -
REPEAT - AgraFlora Organics Reviews Delta Greenhouse Infrastructure Upgrades; Deploys Over C$30,000,000 in PPE Expenditures
02/10/2019 - 14:03 -
AgraFlora Organics présente les améliorations réalisées sur l'infrastructure du Delta Greenhouse Complex incluant des dépenses en immobilisations corporelles de plus de 30 millions de dollars canadiens
02/10/2019 - 14:03 -
Celldex Therapeutics Announces Upcoming Data Presentations
02/10/2019 - 14:01 -
BioCardia Announces the Appointment of Two New Board Members
02/10/2019 - 14:00 -
Cue Biopharma to Present Corporate Overview and Update on Clinical Development Progress for CUE-101 at the Cantor 2019 Global Healthcare Conference
02/10/2019 - 14:00 -
Demant A/S: Change of date of publication of Interim Management Statement
02/10/2019 - 09:53 -
AgraFlora Organics Reviews Delta Greenhouse Infrastructure Upgrades; Deploys Over C$30,000,000 in PPE Expenditures
02/10/2019 - 09:01 -
New Data Presented on ASLAN’s varlitinib at ESMO 2019
02/10/2019 - 08:30 -
Nexstim Plc in Technology Licensing Discussions with a Leading California Based Academic Institution
02/10/2019 - 08:00 -
Top Line Results from Glaucoma Dolomites Phase 2 Trial Show Nicox’s NCX 470 Meets Primary Endpoint and Demonstrates Statistical Superiority vs Latanoprost
02/10/2019 - 07:30 -
Nicox : Les premiers résultats de l’étude de phase 2 Dolomites dans le glaucome montrent que le NCX 470 atteint le critère d’évaluation primaire et démontre une supériorité statistique vs. latanoprost
02/10/2019 - 07:30 -
Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at 27th Annual Meeting of the European Orthopaedic Research Society
02/10/2019 - 07:21 -
Bone Therapeutics présentera des données précliniques sur les propriétés ostéogéniques d’ALLOB dans la régénération osseuse à l’occasion de la 27e réunion annuelle de l’EORS (European Orthopaedic Research Society)
02/10/2019 - 07:21
Pages